psilocybin – Page 5

Love (Drugs), Happiness, and Morality

mycolabadmin

This paper argues that love, happiness, and moral behavior create a self-reinforcing cycle: moral actions increase happiness, happiness promotes loving feelings, and love encourages more moral behavior. The author proposes that psilocybin and other love-enhancing drugs could strengthen this beneficial cycle, making them an ethical way for people to voluntarily improve themselves and society without requiring government mandates.

The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study

mycolabadmin

A 70-year-old man suffering from severe depression and anxiety caused by chronic Lyme disease and related tick-borne infections found relief after taking small doses of psilocybin mushrooms three times a week. Within days of starting treatment, his mood improved dramatically, and he remained symptom-free for two years. This case suggests that psilocybin’s ability to reduce inflammation in the brain may help patients with infectious-caused psychiatric conditions who cannot tolerate standard medications.

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects

mycolabadmin

This study directly compared two popular psychedelic drugs, LSD and psilocybin (magic mushrooms), in 28 healthy volunteers. Researchers found that these substances produce very similar mental effects when given at equivalent doses, with the main difference being that LSD lasts longer. The study establishes that about 20 milligrams of psilocybin is roughly equivalent to 100 micrograms of LSD. These findings could help guide dosing for future psychiatric treatments using these psychedelics.

The Impact of Psilocybin on High Glucose/Lipid-Induced Changes in INS-1 Cell Viability and Dedifferentiation

mycolabadmin

Researchers tested whether psilocybin, a compound from magic mushrooms, could protect pancreatic β-cells (which produce insulin) from damage caused by high glucose and fat levels. Using laboratory cells, they found that psilocybin reduced β-cell death by preventing apoptosis and showed promise in reducing dedifferentiation (when cells lose their specialized functions). However, psilocybin didn’t restore the cells’ ability to respond to glucose by releasing insulin.

Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression

mycolabadmin

This research study is investigating how psilocybin, a compound from certain mushrooms, affects the brain in people with depression. The study involves 50 participants who will receive either psilocybin or a placebo, with their brain activity monitored using advanced imaging scans. Researchers will examine how psilocybin changes blood flow and network activity in brain regions involved in mood regulation, and whether these changes are linked to improvements in depression symptoms.

The association between diverse psychological protocols and the efficacy of psilocybin-assisted therapy for clinical depressive symptoms: a Bayesian meta-analysis

mycolabadmin

This research examined how different types of psychological support during psilocybin treatment affect depression outcomes. Researchers analyzed 10 clinical trials involving 515 patients with depression. They found that whether therapists used structured manuals or flexible approaches, or whether therapy was directive or non-directive, the depression improvement from psilocybin treatment was similar across all approaches.

Serotonin and psilocybin activate 5-HT1B receptors to suppress cortical signaling through the claustrum

mycolabadmin

Researchers found that serotonin and psilocybin (the active compound in magic mushrooms) work through the same brain mechanism to suppress certain neural signals in a brain region called the claustrum. This region controls how different parts of the cortex communicate with each other. The study shows that psilocybin directly targets serotonin 5-HT1B receptors to quiet down signals from one brain area to another, which may explain how psychedelics change cortical network activity and alter consciousness.

A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia

mycolabadmin

Australia has recently approved psilocybin and MDMA for treating severe depression and PTSD when used with professional therapy support. This paper creates a comprehensive guide outlining all the regulatory, professional, and safety considerations needed to safely deliver these treatments in clinical settings. The researchers interviewed 11 experts and reviewed existing research to identify 102 specific matters that need clear guidelines, such as what qualifications therapists need, where treatments can be delivered, how patients should be screened, and what safety measures are essential.

Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder

mycolabadmin

Researchers tested whether watching nature videos during psilocybin therapy could improve treatment for alcohol addiction. Twenty participants received psilocybin sessions while either watching nature videos or using standard procedures with eyeshades and music. The study found that nature videos significantly reduced the blood pressure increases that normally occur with psilocybin, while maintaining the same therapeutic benefits for reducing alcohol use and promoting meaningful experiences.

DNA Authentication and Chemical Analysis of Psilocybe Mushrooms Reveal Widespread Misdeterminations in Fungaria and Inconsistencies in Metabolites

mycolabadmin

Researchers examined museum specimens of magic mushrooms and found that many are mislabeled and don’t reliably contain the psychoactive compounds they should. The study shows that psilocybin breaks down unpredictably during storage, and these mushrooms contain thousands of unknown chemical compounds. These findings suggest that current regulations and our understanding of these mushrooms need significant updates.

Research Topic: psilocybin